{"brief_title": "A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly", "brief_summary": "The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.", "condition": ["Acromegaly"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Pegvisomant", "Sandostatin LAR"], "criteria": "Inclusion Criteria: - Diagnosis of acromegaly - IGF-I levels >=1.3xULN (upper limit of normal) at screening - No history of radiotherapy or prior treatment with other drugs for acromegaly - Minimum of two months must have elapsed post surgery prior to screening Exclusion Criteria: - Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations - AST/ALT >= 3xULN (upper limit of normal) - Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI - Visual field defects (except post surgical stable residual defects) - Unable to self administer drug", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Acromegaly", "Octreotide"], "id": "NCT00068042"}